Cerus Corporation
Update in progressCERS (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryMedical Devices
Cerus Corporation develops and commercializes the INTERCEPT Blood System, a technology that reduces blood-borne pathogens in donated blood components for transfusion. It offers INTERCEPT systems for platelets, plasma, cryoprecipitation, red blood cells, and an LED-based INTERCEPT Illuminator. Sales occur through direct channels and distributors worldwide. Formerly Cerus Technologies Inc, renamed in 1996; founded in 1991 and headquartered in Concord, California.
Company score
- Sentiment
- 0.46
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.46
- Governance
- 0.18
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.18
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.32
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEOMr. Vivek K. Jayaraman
- Founded1991
- Employees261
- Websitewww.cerus.com
Identifiers
- ISINUS1570851014
- FIGIBBG000HBVZX8
- LEI254900BIEY9XIDA04Q21
- CUSIP157085101
- CIK0001020214